Jan 10, 2023 / 10:15PM GMT
Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst
All right. Good afternoon. I'm Julia Qin, lead analyst covering life science tools and diagnostics at JPMorgan. And it's my great pleasure to introduce you to our next company presentation by Repligen.
With that, let me turn it over to Tony. Welcome.
Anthony J. Hunt - Repligen Corporation - President, CEO & Director
Great. Thanks, Julia. Delighted to be here. So I look forward to bringing you guys up to speed on all the things going on at Repligen. I thought it might be useful for the first few minutes to give the audience a little overview of where I see the bioprocessing industry as we enter 2023. There's been lots of questions on this. So, I think if you look back over the last 5 years, tremendous growth in bioprocessing, really started mid-2018, and it's been really fueled by increased number of approvals to monoclonal antibodies. There has been a significant investment in cell and gene therapy, which has spawned a whole set of companies that have scaled and started to use
Repligen Corp at JPMorgan Healthcare Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers